PERINTAH RACUN (PINDAAN SENARAI RACUN) 2019

dengan memasukkan selepas butiran “Dapsone” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Daratumumab - All preparations”;

dengan memasukkan selepas butiran “Dipyrone” dan butir-butir yang berhubungan dengannya butiran yang berikut:

8

Names

dengan memasukkan selepas butiran “Elaterin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

“Elbasvir

dengan memasukkan selepas butiran “Emepromium; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

9

Names Part I Part II Exempt

Group A Group B Group C Group D

“Emodepside - - All preparations”;

dengan memasukkan selepas butiran “Eplerenone” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Eprinomectin - All preparations”;

dengan memasukkan selepas butiran “N-ethyl MDA (DD)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

10

Names Part I Part II Exempt

Group A Group B Group C Group D

“Ethylone (3,4-

Methylenedioxy-N-ethylcathinone)

- All preparations

Ethylphenidate - All preparations”;

dengan memasukkan selepas butiran “[1-(5-fluoropentyl)-1H-indol-3-yl](naphthalen-1-yl)methanone (AM-2201)”

dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“[1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3-

tetrametylcyclopropyl)

methanone (XLR-11)

- All preparations”;

11

dengan memasukkan selepas butiran “Glucagon; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dengan memasukkan selepas butiran “Granisetron; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Grazoprevir - All preparations”;

12

dengan memasukkan selepas butiran “8-[N-(2-hydroxyethyl)-methyl-amino]-1, 3, 7 trimethylxanthine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dengan menggantikan butiran “Iodine” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Iodine - - All preparations for parenteral administration. All medicinal

All preparations unless in

Group C or

-

Preparations containing less than 2%

of iodine

13

preparations containing 2% and above of iodine exempted unless in

Group C”

dengan memasukkan selepas butiran “Methimazole; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Methiopropamine (MPA) - All preparations”;

dengan memasukkan selepas butiran “Methotrexate; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Methoxetamine (MXE) - All preparations”;

14

dengan memasukkan selepas butiran “N-Methylephedrine camsylate” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“4-Methylethcathinone

(4-MEC)

- All preparations

3- Methylmethcathinone

(3-MMC)

- All preparations

Methyl 2-({[1-(5-

fluoropentyl)-1H-indazol-3-yl]

carbonyl}amino)-3-

methylbutanoate (5F-AMB)

- All preparations”;

15

dengan memasukkan selepas butiran “Miltefosine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dalam butiran “Narcotic substances, the following: their isomers (whenever the existence of such isomers is possible within the specific chemical designation); their salts; their esters and ethers (whenever the existence of such esters or ethers is possible); the salts of their esters and ethers–”—

16

dengan memasukkan selepas butiran “(DD) Acetyldihydrocodeine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“(DD) Acetylfentanyl - All preparations”;

dengan menggantikan butiran “(DD) 4-bromo-2,5-dimethoxyphenylethylamine (2C-B)” dan butir-butir yang berhubung dengannya dengan butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“(DD) 4-bromo-2,5-

dimethoxyphenethy lamine (2C-B)

All preparations

All

Butyrfentanyl -

preparations”;

17

dengan memasukkan selepas butiran “(DD) Codoxime” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“(DD) 1-Cyclohexyl-4-(1,2-

diphenylethyl)piperazine

(MT-45)

- All preparations”;

dengan memasukkan selepas butiran “(DD) Diampromide” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

Group

A

Group B Group C Group D

“(DD) 3,4-Dichloro-N-[(1-

dimethylamino)

cyclohexylmethyl]benzami de (AH-7921)

- All preparations

18

3,4-Dichloro-N-[2-

(dimethylamino)cyclohexy]

-N-methylbenzamide

(U-47700)

- All preparations”;

dengan menggantikan butiran “(DD) Remifentanil” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“(DD) Remifentanil - All products registered under the Control of Drugs and Cosmetics

Regulations 1984”;

dengan memasukkan selepas butiran “Nebivolol” dan butir-butir yang berhubungan dengannya butiran yang berikut:

19

Names Part I Part II Exempt

Group A Group B Group C Group D

“Necitumumab - All preparations”;

dengan memasukkan selepas butiran “Nialamide” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Nicarbazin - All preparations”;

dengan memasukkan selepas butiran “Oseltamivir” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Osimertinib - All preparations”;

20

dengan memasukkan selepas butiran “Paramethoxyamphetamine (PMA) (DD)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Para-methoxymethylamphetamine

(PMMA) (DD)

Para-methyl-4-

methylaminorex (4,4’-DMAR)

-

All preparations

- All preparations”;

dengan memasukkan selepas butiran “Pentazocine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Pentedrone (α-

methylaminovalerophenone)

-

All preparations”;

21

dengan memasukkan selepas butiran “Phenethylamine unless specified elsewhere in the List” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“N-Phenethyl-4-

piperidinone

(NPP)

- - - - All preparations”;

dengan memasukkan selepas butiran “Phenmetrazine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Phenolphthalein - - All preparations for therapeutic use

-

All preparations unless in

Group C”;

22

dengan memasukkan selepas butiran “Pyrovalerone” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“α-Pyrrolidinovalerophenone

(α-PVP)

- All preparations”;

dengan memasukkan selepas butiran “Quinine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Quinolin-8-yl 1-(5-

fluoropentyl)-1H-indole-3-

carboxylate (5F-PB-

22)

- All preparations”;

23

dengan memasukkan selepas butiran “Rizatriptan; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Robenidine - All preparations”;

dengan memasukkan selepas butiran “Styramate” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Succinylated gelatin

-

- All preparations for parenteral administration

-

- All preparations unless in

Group C”;

24

dengan memasukkan selepas butiran “Triflusal” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Triglycerides - - All preparations for parenteral administration

-

- All preparations unless in

Group C”;

dalam butiran “Vitamins, the following:”, dengan memasukkan selepas butiran “Mecobalamin” butiran

“Menaquinone”; dan

dalam Lampiran kepada Senarai Racun—

dalam senarai “Anaesthetics” dengan memasukkan selepas butiran “Local anaesthetics, the following: their salts;

their homologues and analogues; their molecular compounds” butiran “Methoxetamine (MXE)”;

dalam senarai “Analeptics and Central Stimulants”—

25

dengan memasukkan selepas butiran “N-Ethyl MDA (DD)” butiran yang berikut:

“Ethylone (3,4-Methylenedioxy-N-ethylcathinone)

Ethylphenidate”;

dengan memasukkan selepas butiran “Methcathinone (DD)” butiran “Methiopropamine (MPA)”;

dengan memasukkan selepas butiran “3, 4-Methylenedioxymetamphetamine (MDMA) (DD)” butiran yang berikut:

“4-Methylethcathinone (4-MEC)

3- Methylmethcathinone (3-MMC)”;

dengan memasukkan selepas butiran “Paramethoxyamphetamine (PMA) (DD)” butiran yang berikut:

“Para-methoxymethylamphetamine (PMMA) (DD)

Para-methyl-4-methylaminorex (4,4’-DMAR)”;

dengan memasukkan selepas butiran “Pemoline; its salts” butiran “Pentedrone

(α- methylaminovalerophenone)”; dan

dengan memasukkan selepas butiran “Pyrovalerone” butiran “α-Pyrrolidinovalerophenone (α-PVP)”;

26

dalam senarai “Analgesics including antipyretic and anti-inflammatory agents”—

dengan memasukkan selepas butiran “Acetanilide; alkylacetanilides” butiran yang berikut:

“N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-APINACA)

N-(Adamantan-1-yl)-1-pentyl-1H-indazole-3-carboxamide (APINACA)”;

dengan memasukkan selepas butiran “Amidopyrine; its salts” butiran “N- [(1S) - 1-

(Aminocarbonyl) - 2-

methylpropyl] - 1-

(cyclohexylmethyl) 1H-indazole- 3- carboxamide (AB-CHMINACA)”;

dengan memasukkan selepas butiran “Cinchophen and other substances structurally derived from 4 quinolinecarboxylic acid unless specified elsewhere in the list; their salts and esters” butiran “N-{[1-

(Cyclohexylmethyl)-1H-indol-3yl]carbonyl}-3-methyl-L-valinate (MDMB-CHMICA)”;

dengan memasukkan selepas butiran “Flunixin” butiran “[1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3-

tetrametylcyclopropyl) methanone (XLR-11)”;

dengan memasukkan selepas butiran “Mesalazine” butiran “Methyl 2-({[1-(5-fluoropentyl)-1H-indazol-3-yl]

carbonyl}amino)-3-methylbutanoate (5F-AMB)”; dan 27

dengan memasukkan selepas butiran “Proquazone” butiran “Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-

carboxylate (5F-PB-22)”;

dalam senarai “Anthelmintics” dengan memasukkan selepas butiran “Doramectin” butiran “Emodepside”;

dalam senarai “Antifungals and Antiprotozoals”—

dengan memasukkan selepas butiran “Natamycin” butiran “Nicarbazin”; dan

dengan memasukkan selepas butiran “Posaconazole” butiran “Robenidine”;

dalam senarai “Antineoplastic agents and Immunosuppressants”—

dengan memasukkan selepas butiran “L-Asparaginase” butiran “Atezolizumab”;

dengan memasukkan selepas butiran “Carboplatin” butiran “Carfilzomib”;

dengan memasukkan selepas butiran “Dacliximab” butiran “Daratumumab”;

dengan memasukkan selepas butiran “Natalizumab” butiran “Necitumumab”; dan 28

dengan memasukkan selepas butiran “Orthopterin” butiran “Osimertinib”;

dalam senarai “Antiviral agents”—

dengan memasukkan selepas butiran “Efavirenz” butiran “Elbasvir”; dan

dengan memasukkan selepas butiran “Ganciclovir” butiran “Grazoprevir”;

dalam senarai “Narcotics”—

dengan memasukkan selepas butiran “(DD) Acetyldihydrocodeine” butiran “(DD) Acetylfentanyl”;

dengan memasukkan selepas butiran “(DD) 4-bromo-2, 5-dimethoxyphenethylamine (2C-B)” butiran

“(DD)Butyrfentanyl”;

dengan memasukkan selepas butiran “(DD) Codoxime” butiran “(DD) 1-Cyclohexyl-4-(1,2-

diphenylethyl)piperazine (MT-45)”; dan

dengan memasukkan selepas butiran “(DD) Diampromide” butiran yang berikut:

29

“(DD) 3,4-Dichloro-N-[(1-dimethylamino) cyclohexylmethyl]benzamide (AH-7921)

3,4-Dichloro-N-[2-

(dimethylamino)cyclohexyl]-N-methylbenzamide

(U-47700)”; dan

dalam senarai “Miscellaneous”—

dengan memasukkan selepas butiran “Afoxolaner” butiran “Albutrepenonacog alfa”;

dengan memasukkan selepas butiran “Amifostine, its salts; its esters” butiran “Amino acids, unless specified elsewhere in the List”;

dengan memasukkan selepas butiran “Anagrelide” butiran “4-Anilino-N-phenethylpiperidine (ANPP)”;

dengan memasukkan selepas butiran “Becaplermin” butiran “Beroctocog alfa”;

dengan memasukkan selepas butiran “Dinitrothymols” butiran “Diquafosol”;

dengan memasukkan selepas butiran “Eltrombopag” butiran “Eprinomectin”;

dengan memasukkan selepas butiran “Glucagon; its salts” butiran “Glucose”;

30

dengan memasukkan selepas butiran “Hydrogen cyanide; metal cyanides other than ferrocyanides and ferricyanides” butiran “Hydroxyethylstarch”;

dengan memasukkan selepas butiran “Metyrapone; its salts” butiran yang berikut:

“Minerals; the following, unless specified elsewhere in the List:

Chromium

Copper

Fluorine

Iron

Manganese

Selenium

Zinc”;

dengan memasukkan selepas butiran “Pentosan” butiran yang berikut:

“N-Phenethyl-4-piperidinone (NPP)

Phenolphthalein”;

dengan memasukkan selepas butiran “Stavesacre; alkaloids of” butiran “Succinylated gelatin”;

31

dengan memasukkan selepas butiran “Triflusal” butiran “Triglycerides”; dan

dalam butiran “Vitamin; the following:” dengan memasukkan selepas butiran “Mecobalamin” butiran

“Menaquinone”.

Dibuat 18 Disember 2018

[KKM.R.600-1/1/56; PN(PU2)172/XII]

DATUK SERI DR. DZULKEFLY BIN AHMAD

Menteri Kesihatan

32

POISONS ACT 1952

POISONS (AMENDMENT OF POISONS LIST) ORDER 2019

in the Poisons List—

by inserting after the item “Adalimumab” and the particulars relating to it the following items:

33

Names Part I Part II Exempt

Group A Group B Group C Group D

“N-(Adamantan-1-yl)-1-(5-

fluoropentyl)-1H-indazole-3-

carboxamide (5F-APINACA)

- All preparations

N-(Adamantan-1-yl)-1-

pentyl-1H-indazole-3-

carboxamide (APINACA)

- All preparations”;

by inserting after the item “Agomelatine” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Albutrepenonacog alfa - All preparations”;

by inserting after the item “Amilsulpride” and the particulars relating to it the following items:

34

Names Part I Part II Exempt

Group A Group B Group C Group D

“Amino acids, unless specified elsewhere in the

List

-

- All preparations for parenteral administration

-

- All preparations unless in Group C

N- [(1S) - 1-

(Aminocarbonyl) - 2-

methylpropyl] - 1-

(cyclohexylmethyl) 1H-indazole- 3- carboxamide

(AB-CHMINACA)

- All preparations”;

by inserting after the item “Anidulafungin” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“4-Anilino-N-phenethylpiperidine

(ANPP)

- - - - All preparations”;

35

by inserting after the item “Atenolol; its salts” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Atezolizumab - All preparations”;

by inserting after the item “Bepridil; its salts” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Beroctocog alfa - All preparations”;

by inserting after the item “Carfentanil citrate” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Carfilzomib - All preparations”;

by inserting after the item “Cyclofenil” and the particulars relating to it the following item:

36

Group A

Group B

Group C

Group D

-

All preparations”;

Names Part I Part II Exempt

Group A Group B Group C Group D

“N-{[1-

(Cyclohexylmethyl)-1H-indol-3yl]carbonyl}-3-

methyl-L-valinate

(MDMB-CHMICA)

- All preparations”;

by inserting after the item “Dapsone” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Daratumumab - All preparations”;

by inserting after the item “Dipyrone” and the particulars relating to it the following item:

Names Part I Part II Exempt

“Diquafosol

37

by inserting after the item “Elaterin” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Elbasvir - All preparations”;

by inserting after the item “Emepromium; its salts” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Emodepside - - All preparations”;

by inserting after the item “Eplerenone” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Eprinomectin - All preparations”;

38

by inserting after the item “N-ethyl MDA (DD)” and the particulars relating to it the following items:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Ethylone (3,4-

Methylenedioxy-N-ethylcathinone)

- All preparations

Ethylphenidate - All preparations”;

by inserting after the item “[1-(5-fluoropentyl)-1H-indol-3-yl](naphthalen-1-yl) methanone (AM-2201)” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“[1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3-

tetrametylcyclopropyl)

methanone (XLR-11)

- All preparations”;

39

by inserting after the item “Glucagon; its salts” and the particulars relating to it the following item:

Names

by inserting after the item “Granisetron; its salts” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Grazoprevir - All preparations”;

40

by inserting after the item “8-[N-(2-hydroxyethyl)-methyl-amino]-1, 3, 7 trimethylxanthine” and the particulars relating to it the following item:

Names

by substituting for the item “Iodine” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Iodine - - All preparations for parenteral administration.

All medicinal preparations containing 2%

and above of iodine

All preparations unless in

Group C or exempted

-

Preparations containing less than 2% of iodine unless in

Group C”;

41

by inserting after the item “Methimazole; its salts” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Methiopropamine (MPA) - All preparations”;

by inserting after the item “Methotrexate; its salts” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Methoxetamine (MXE) - All preparations”;

by inserting after the item “N-Methylephedrine camsylate” and the particulars relating to it the following items:

Names Part I Part II Exempt

Group A Group B Group C Group D

“4-Methylethcathinone (4-MEC) - All preparations

42

3- Methylmethcathinone

(3-MMC)

- All preparations

Methyl 2-({[1-(5-fluoropentyl)-

1H-indazol-3-yl]

carbonyl}amino)-3-

methylbutanoate (5F-AMB)

- All preparations”;

by inserting after the item “Miltefosine” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Minerals; the following, unless specified elsewhere in the List:

Chromium

Copper

Fluorine

Iron

Manganese

Selenium

Zinc

-

- All preparations for parenteral administration

- - All preparations unless in Group C”;

43

in the item “Narcotic substances, the following: their isomers (whenever the existence of such isomers is possible within the specific chemical designation); their salts; their esters and ethers (whenever the existence of such esters or ethers is possible); the salts of their esters and ethers –” —

by inserting after the item “(DD) Acetyldihydrocodeine” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“(DD) Acetylfentanyl - All preparations”;

by substituting for the item “(DD) 4-bromo-2,5-dimethoxyphenylethylamine (2C-B)” and the particulars relating to it the following items:

Names Part I Part II Exempt

Group A Group B Group C Group D

“(DD) 4-bromo-2,5-

dimethoxyphenethy lamine (2C-B)

All preparations

44

Butyrfentanyl - All preparations”;

by inserting after the item “(DD) Codoxime” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“(DD) 1-Cyclohexyl-4-(1,2-

diphenylethyl)piperazine

(MT-45)

- All preparations”;

by inserting after the item “(DD) Diampromide” and the particulars relating to it the following items:

Names Part I Part II Exempt

Group A Group B Group C Group D

“(DD) 3,4-Dichloro-N-

[(1-dimethylamino)

cyclohexylmethyl]benzami de (AH-7921)

- All preparations

45

3,4-Dichloro-N-[2-

(dimethylamino)cyclohe xyl]-N-methylbenzamide

(U-47700)

- All preparations”;

by substituting for the item “(DD) Remifentanil” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“(DD) Remifentanil - All products registered under the Control of Drugs and Cosmetics

Regulations 1984”;

46

by inserting after the item “Nebivolol” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Necitumumab - All preparations;

by inserting after the item “Nialamide” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Nicarbazin - All preparations”;

by inserting after the item “Oseltamivir” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Osimertinib - All preparations”;

47

by inserting after the item “Paramethoxyamphetamine (PMA) (DD)” and the particulars relating to it the following items:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Para-methoxymethylamphetamine

(PMMA) (DD)

Para-methyl-4-

methylaminorex (4,4’-DMAR)

- All preparations

- All preparations”;

by inserting after the item “Pentazocine; its salts” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Pentedrone (α-

methylaminovalerophenone)

- All preparations”;

48

by inserting after the item “Phenethylamine” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“N-Phenethyl-4-

piperidinone

(NPP)

- - - - All preparations”;

by inserting after the item “Phenmetrazine; its salts” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Phenolphthalein - - All preparations for therapeutic use

-

All preparations unless in Group C”;

49

by inserting after the item “Pyrovalerone” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“α-Pyrrolidinovalerophenone

(α-PVP)

- All preparations”;

by inserting after the item “Quinine; its salts” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Quinolin-8-yl 1-(5-

fluoropentyl)-1H-indole-3-

carboxylate (5F-PB-

22)

- All preparations”;

50

by inserting after the item “Rizatriptan; its salts” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Robenidine - All preparations”;

by inserting after the item “Styramate” and the particulars relating to it the following item:

Names

by inserting after the item “Triflusal” and the particulars relating to it the following item:

Names Part I Part II Exempt

Group A Group B Group C Group D

“Triglycerides - - All preparations for parenteral

- - All preparations

51

administration unless in Group C”;

in the item “Vitamins, the following:”, by inserting after the item “Mecobalamin” and the particulars relating to it the item “Menaquinone”; and

in the Appendix to the Poisons List—

in the list of “Anaesthetics” by inserting after the item “Local anaesthetics, the following: their salts; their homologues and analogues; their molecular compounds” the item “Methoxetamine (MXE)”;

in the list of “Analeptics and Central Stimulants”—

by inserting after the item “N-Ethyl MDA (DD)” the following items:

“Ethylone (3,4-Methylenedioxy-N-ethylcathinone)

Ethylphenidate”;

by inserting after the item “Methcathinone (DD)” the item “Methiopropamine (MPA)”;

by inserting after the item “3, 4-Methylenedioxymetamphetamine (MDMA) (DD)” the following items:

52

“4-Methylethcathinone (4-MEC)

3-Methylmethcathinone (3-MMC)”;

by inserting after the item “Paramethoxyamphetamine (PMA) (DD)” the following items:

“Para-methoxymethylamphetamine (PMMA) (DD)

Para-methyl-4-methylaminorex (4,4’-DMAR)”;

by inserting after the item “Pemoline; its salts” the item “Pentedrone (α-methylaminovalerophenone)”; and

by inserting after the item “Pyrovalerone” the item “α-Pyrrolidinovalerophenone (α-PVP)”;

in the list of “Analgesics including antipyretic and anti-inflammatory agents”—

by inserting after the item “Acetanilide; alkylacetanilides” the following items:

“N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-APINACA)

N-(Adamantan-1-yl)-1-pentyl-1H-indazole-3-carboxamide (APINACA)”;

53

by inserting after the item “Amidopyrine; its salts” the item “N- [(1S) - 1-

(Aminocarbonyl) - 2- methylpropyl] -

1-

(cyclohexylmethyl) 1H-indazole- 3- carboxamide (AB-CHMINACA)”;

by inserting after the item “Cinchophen and other substances structurally derived from 4 quinolinecarboxylic acid unless specified elsewhere in the List; their salts and esters” the item “N-{[1-

(Cyclohexylmethyl)-1H-indol-

3yl]carbonyl}-3-methyl-L-valinate (MDMB-CHMICA)”;

by inserting after the item “Flunixin” the item “[1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3-

tetrametylcyclopropyl) methanone (XLR-11)”;

by inserting after the item “Mesalazine” the item “Methyl 2-({[1-(5-fluoropentyl)-1H-indazol-3-yl]

carbonyl}amino)-3-methylbutanoate (5F-AMB)”; and

by inserting after the item “Proquazone” the item “Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3- carboxylate

(5F-PB-22)”;

in the list of “Anthelmintics”, by inserting after the item “Doramectin” the item “Emodepside”;

in the list of “Antifungals and Antiprotozoals”—

by inserting after the item “Natamycin” the item “Nicarbazin”; and

54

by inserting after the item “Posaconazole” the item “Robenidine”;

in the list of “Antineoplastic agents and Immunosuppressants”—

by inserting after the item “L-Asparaginase” the item “Atezolizumab”;

by inserting after the item “Carboplatin” the item “Carfilzomib”;

by inserting after the item “Dacliximab” the item “Daratumumab”;

by inserting after the item “Natalizumab” the item “Necitumumab”; and

by inserting after the item “Orthopterin” the item “Osimertinib”;

in the list of “Antiviral agents”—

by inserting after the item “Efavirenz” the item “Elbasvir”; and

by inserting after the item “Ganciclovir” the item “Grazoprevir”;

55

in the list of “Narcotics” —

by inserting after the item “(DD) Acetyldihydrocodeine” the item “(DD) Acetylfentanyl”;

by inserting after the item “(DD) 4-bromo-2, 5-dimethoxyphenylethylamine (2C-B)” the item

“(DD)Butyrfentanyl”;

by inserting after the item “(DD) Codoxime” the item “(DD) 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine

(MT-45)”; and

by inserting after the item “(DD) Diampromide” the following items:

“(DD) 3,4-Dichloro-N-[(1-dimethylamino) cyclohexylmethyl]benzamide (AH-7921)

3,4-Dichloro-N-[2-

(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700)”; and

in the list of “Miscellaneous”—

by inserting after the item “Afoxolaner” the item “Albutrepenonacog alfa”;

56

by inserting after the item “Amifostine; its salts; its esters” the item “Amino acids, unless specified elsewhere in the List”;

by inserting after the item “Anagrelide” the item “4-Anilino-N-phenethylpiperidine (ANPP)”;

by inserting after the item “Becaplermin” the item “Beroctocog alfa”;

by inserting after the item “Dinitrothymols” the item “Diquafosol”;

by inserting after the item “Eltrombopag” the item “Eprinomectin”;

by inserting after the item “Glucagon; its salts” the item “Glucose”;

by inserting after the item “Hydrogen cyanide; metal cyanides other than ferrocyanides and ferricyanides” the item “Hydroxyethylstarch”;

by inserting after the item “Metyrapone; its salts” the following item:

“Minerals; the following, unless specified elsewhere in the List:

Chromium

Copper

Fluorine

57

Iron

Manganese

Selenium

Zinc”;

by inserting after the item “Pentosan” the following items:

“N-Phenethyl-4-piperidinone (NPP)

Phenolphthalein”;

by inserting after the item “Stavesacre, alkaloids of” the item “Succinylated gelatin”;

by inserting after the item “Triflusal” the item “Triglycerides”; and

in the item “Vitamin; the following:” by inserting after the item “Mecobalamine” the item “Menaquinone”.

Made 18 December 2018

[KKM.R.600-1/1/1/56; PN(PU2)172/XII]

DATUK SERI DR. DZULKEFLY BIN AHMAD

Minister of Health